By Jaime Llinares Taboada

AstraZeneca PLC said Thursday that the combination of its Imfinzi immunotherapy with tremelimumab antibodies improved survival in lung cancer patients.

The pharmaceutical company said Imfinzi and tremelimumab with chemotherapy improved overall survival by 23% in 1st-line Stage IV non-small cell lung cancer at a Phase 3 trial.

"Adding a short course of tremelimumab to Imfinzi for those patients already receiving chemotherapy, reduced the risk of cancer progressing or death by 28% compared to chemotherapy alone," said Susan Galbraith, AstraZeneca's executive vice president at Oncology R&D.

Write to Jaime Llinares Taboada at jaime.llinares@wsj.com; @JaimeLlinaresT

(END) Dow Jones Newswires

September 09, 2021 11:28 ET (15:28 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
AstraZeneca (NASDAQ:AZN)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024 Click aqui para mais gráficos AstraZeneca.
AstraZeneca (NASDAQ:AZN)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024 Click aqui para mais gráficos AstraZeneca.